Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Evotec SE

Biotech Giants' SG&A Expenses: A Decade of Divergence

__timestampEvotec SEInsmed Incorporated
Wednesday, January 1, 20141799000031073000
Thursday, January 1, 20152516600043216000
Friday, January 1, 20162701300050679000
Sunday, January 1, 20174238300079171000
Monday, January 1, 201857012000168218000
Tuesday, January 1, 201966546000210796000
Wednesday, January 1, 202077238000203613000
Friday, January 1, 2021105445000234273000
Saturday, January 1, 2022156190000265784000
Sunday, January 1, 2023169610000344501000
Loading chart...

Data in motion

A Decade of SG&A Evolution: Insmed vs. Evotec

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Insmed Incorporated and Evotec SE have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Evotec's expenses grew by approximately 840%, indicating a more measured approach.

Key Insights

  • 2014-2018: Insmed's expenses grew rapidly, outpacing Evotec by nearly 50% by 2018.
  • 2019-2023: Both companies saw significant increases, but Insmed maintained a lead, with expenses peaking at 344% higher than Evotec by 2023.
    This analysis underscores the strategic differences between these biotech giants, offering a window into their operational priorities and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025